| Budget Amount *help |
¥45,500,000 (Direct Cost: ¥35,000,000、Indirect Cost: ¥10,500,000)
Fiscal Year 2019: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2018: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2017: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2016: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2015: ¥10,140,000 (Direct Cost: ¥7,800,000、Indirect Cost: ¥2,340,000)
|
|---|
| Outline of Final Research Achievements |
We developed a pre-targeted method by which target cells could be selectively imaged using a labeled N-glycan that was ligated in situ with a high-affinity peptide ligand on the cell surface. We demonstrated the power of this method in discriminating various cancer and non-cancerous cells that cannot be distinguished using conventional integrin-targeted paptide ligands. Using various integrin-targeted peptides and N-glycans with various linker lengths, we identified optimal combinations to discriminate several types of integrin–expressing cells on 96-well plates. The optimal combinations of peptide and N-glycan ligands for the target cells were fingerprinted on the plates, and then used to selectively image tumors in xenografted mouse models. Using this method, various N-glycan molecules, even those with millimolar affinities for their cognate lectins, could be used for selective cancer cell differentiation.
|
